Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?

1. RVMD presents data for zoldonrasib targeting KRAS G12D mutant NSCLC. 2. Notable safety profile reported, consistent with previous pancreatic cancer data. 3. Objective response rate for NSCLC patients reached 61%, disease control rate at 89%. 4. Price action shows RVMD stock increased 6.76% to $41.39. 5. CEO emphasizes ongoing efforts for innovative treatment of hard-to-treat cancers.